Teleflex (NYSE:TFX) Issues FY 2026 Earnings Guidance

Teleflex (NYSE:TFX) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 6.250-6.550 for the period, compared to the consensus EPS estimate of 6.730. The company issued revenue guidance of $2.3 billion-$2.3 billion, compared to the consensus revenue estimate of $2.3 billion.

Teleflex Trading Up 1.1%

NYSE TFX traded up $1.49 on Friday, hitting $133.17. The company’s stock had a trading volume of 935,885 shares, compared to its average volume of 967,414. Teleflex has a 52-week low of $100.18 and a 52-week high of $139.67. The company has a current ratio of 2.54, a quick ratio of 2.01 and a debt-to-equity ratio of 0.81. The company’s 50-day simple moving average is $119.44 and its 200 day simple moving average is $116.73. The firm has a market cap of $5.89 billion, a P/E ratio of -6.48, a PEG ratio of 0.89 and a beta of 0.82.

Teleflex (NYSE:TFX) last released its quarterly earnings data on Thursday, May 7th. The medical technology company reported $1.39 earnings per share for the quarter, topping the consensus estimate of $1.21 by $0.18. The business had revenue of $548.30 million during the quarter, compared to analysts’ expectations of $536.91 million. Teleflex had a positive return on equity of 14.30% and a negative net margin of 30.56%.The business’s revenue was up 32.3% on a year-over-year basis. During the same quarter last year, the business posted $1.44 EPS. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. Research analysts predict that Teleflex will post 6.77 EPS for the current fiscal year.

Teleflex Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 31st. Shareholders of record on Friday, March 6th were issued a $0.34 dividend. The ex-dividend date was Friday, March 6th. This represents a $1.36 dividend on an annualized basis and a yield of 1.0%. Teleflex’s dividend payout ratio is -6.62%.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on TFX shares. Raymond James Financial restated an “outperform” rating and set a $150.00 target price on shares of Teleflex in a report on Friday. Needham & Company LLC increased their price target on shares of Teleflex from $138.00 to $147.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Mizuho set a $140.00 price target on shares of Teleflex in a research report on Friday. Zacks Research raised shares of Teleflex from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 28th. Finally, Wall Street Zen upgraded shares of Teleflex from a “sell” rating to a “hold” rating in a report on Saturday, April 25th. Three equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $142.86.

Teleflex News Summary

Here are the key news stories impacting Teleflex this week:

• Positive Sentiment: Q1 beat — Teleflex reported adjusted EPS of $1.39 and revenue of $548.3M, topping estimates and showing 32.3% year‑over‑year revenue growth, a clear near‑term fundamental positive for the shares. Read More.
• Positive Sentiment: Shareholder support — Management reiterated its full‑year outlook and announced a buyback program, which can support the stock over time by reducing float and signaling confidence. Read More.
• Positive Sentiment: Analyst update — Wells Fargo raised its price target to $138 (still an “equal weight” rating), giving a modest additional catalyst for buyers. Read More.
• Neutral Sentiment: Earnings call and presentation — Management’s slide deck and the earnings‑call transcript provide more detail on product trends and geographic performance; these materials help investors model the cadence of recovery but don’t change the headline beat/guidance picture. Read More.
• Negative Sentiment: Cautious guidance — Teleflex set FY2026 adjusted EPS guidance at $6.25–$6.55, below the consensus near $6.73, which tempers the upside from the quarter’s revenue beat. Read More.
• Negative Sentiment: Margin/charges pressure — GAAP diluted EPS from continuing operations was negative and management flagged margin strain on the call (non‑recurring items/adjustments affected reported profitability), raising near‑term earnings uncertainty. Read More.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. UMB Bank n.a. raised its stake in Teleflex by 57.1% during the fourth quarter. UMB Bank n.a. now owns 311 shares of the medical technology company’s stock valued at $38,000 after buying an additional 113 shares during the last quarter. Maryland State Retirement & Pension System raised its stake in Teleflex by 1.5% during the fourth quarter. Maryland State Retirement & Pension System now owns 8,652 shares of the medical technology company’s stock valued at $1,056,000 after buying an additional 129 shares during the last quarter. Osaic Holdings Inc. raised its stake in Teleflex by 17.5% during the second quarter. Osaic Holdings Inc. now owns 1,247 shares of the medical technology company’s stock valued at $148,000 after buying an additional 186 shares during the last quarter. Vident Advisory LLC raised its stake in Teleflex by 2.8% during the fourth quarter. Vident Advisory LLC now owns 6,992 shares of the medical technology company’s stock valued at $853,000 after buying an additional 188 shares during the last quarter. Finally, Empowered Funds LLC raised its stake in Teleflex by 15.8% during the first quarter. Empowered Funds LLC now owns 1,684 shares of the medical technology company’s stock valued at $233,000 after buying an additional 230 shares during the last quarter. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Teleflex Company Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.